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Abstract
Persistent bacteraemia arising from a case of post-operative
mediastinitis as a result of a Proteus mirabilis isolate, possessing
two class 1 integrons carrying blaVIM-1 and aadA2 gene cassettes
located on chromosomal and plasmidic DNA, respectively, is
reported. Despite the in vitro susceptibility to carbapenems, me-
ropenem therapy failed, whereas the patient responded to treat-
ment with cefepime plus amikacin. To our knowledge, this is the
ﬁrst report of metallo-b-lactamase production in a clinical isolate
of P. mirabilis in Italy.
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Metallo-b-lactamase (MBL)-producing strains of Proteus mira-
bilis have been rarely reported in the English literature [1–3].
We describe a case of prolonged bacteraemia due to a VIM-
1 producing P. mirabilis, that did not respond to meropenem
therapy. To our knowledge, this is the ﬁrst case of
severe infection due to a VIM-1-producing P. mirabilis isolate
in Italy.
A diabetic 71-year-old man underwent open heart surgery
with successful replacement of the ascending aorta for acute
dissection. After 10 days in an intensive care unit, the patient
presented with fever and purulent discharge from the stern-
otomy scar. A computed tomography scan of the thorax
showed multiple rim-enhancing ﬂuid collections in the sternal
region that were consistent with mediastinitis. Culture of
wound swabs yielded a strain of P. mirabilis susceptible to
carbapenems, piperacillin/tazobactam, levoﬂoxacin, cefepime
and amikacin. The semiquantitative central venous catheter
tip culture and tracheal aspirate culture were negative. Uri-
nalysis did not reveal leukocyturia, and urine cultures were
negative. The patient underwent surgical debridement and
was given meropenem 1 g thrice daily. However, despite the
treatment, the patient developed severe sepsis. Three sets of
blood cultures yielded P. mirabilis. The dosage of meropenem
was increased to 2 g thrice daily. Surprisingly, the patient
remained febrile and two blood cultures, obtained the next
day, remained positive for the same P. mirabilis. The occur-
rence of bacteraemia prompted the search for endocarditis
or abscesses. Neither transoesophageal echocardiography,
nor total body computed tomography scanning revealed a
possible cause for the therapeutic failure. Therapy was then
shifted to cepeﬁme (2 g every 8 h) plus amikacin (1 g every
24 h). The patient responded to an 8-week course of cefe-
pime plus amikacin therapy (the latter drug was discontinued
after 4 weeks). No relapse was observed after a 3-month
follow-up period.
The P. mirabilis clinical isolate obtained from the patient
was identiﬁed using the automatic system Vitek 2 (bio-
Me´rieux, Inc., Hazelwood, MO, USA), and was conﬁrmed
with API 20E (bioMe´rieux SA, Marcy-l’Etoile, France). The
preliminary antibiotic resistance proﬁle determined by Vitek
2 was conﬁrmed by a broth microdilution method, using
Mueller–Hinton broth, according to guidelines of the CLSI
[4]. The EDTA-imipenem double-disc synergy test was per-
formed as a screening procedure for MBL production [5].
Genomic and plasmid DNA were extracted from P. mirabilis
using Wizard DNA extraction and puriﬁcation kits (Promega,
Milan, Italy). DNA probes, speciﬁc for blaTEM-1, blaSHV-1,
blaCTX-M-1, blaPER-1, blaVIM-1 and blaIMP-1, were labelled with
32P by a random priming technique and were used for South-
ern blot experiments with plasmidic and genomic DNA
transferred onto nylon ﬁlters. Screening for resistance deter-
minants (blaVIM-type and blaTEM-type genes) was performed
by PCR analysis using the primers VIM-F and VIM-R [6] and
TEM/forward (5¢-ATGAGTATTCAACATTTCCG-3¢) and
TEM/reverse (5¢-TTACCAATGCTTAATCAGTGAG-3¢).
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Detection and mapping of a class 1 integron were carried
out using speciﬁc primers for the conserved segments 5¢-CS
(5¢-GGCATCCAAGCAGCAAG-3¢) and 3¢-CS (5¢-CTCTC
AAGATTTTAATGCGGATG-3¢), and then amplifying the
variable region containing the resistance gene cassettes. IntI1,
qacED1 and sul1 were ampliﬁed with speciﬁc primers [5,7].
The DNA fragments obtained by subsequent PCRs were
sequenced on both strands with a ABI-Prism 310 (Applied
Biosystem, Monza, Italy) automatic sequencer. Sequence
analysis was performed on three independent ampliﬁcation
products.
The isolate was susceptible to ceftriaxone (MIC <0.06 mg/
L), ceftazidime (MIC 2 mg/L), cefepime (MIC 0.125 mg/L),
amoxicillin (MIC 1 mg/L), piperacillin/tazobactam (MIC
0.25 mg/L), levoﬂoxacin (MIC 0.12 mg/L) imipenem (MIC
1 mg/L), meropenem (MIC 0.125 mg/L), ertapenem (MIC <
0.125 mg/L), tigecycline (MIC 2 mg/L). The isolate was not
an ESBL producer, but showed a positive EDTA-imipenem
double-disc synergy test. Southern blot analysis showed the
presence of blaVIM-type and blaTEM-type in the P. mirabilis
clinical isolate. The presence of class 1 integrons was
detected by PCR with primers speciﬁc for 5¢- and 3¢-con-
served segments, both in genomic and plasmidic DNA. An
ampliﬁcation product of 1060 bp was obtained from genomic
DNA and direct sequencing revealed one gene cassette car-
rying a blaVIM-1 determinant. In the latter amplicon, a gene
cassette carrying the aadA2 gene (aminoglycoside adenylyl-
transferase) was detected. Both integrons were of class 1
because the integrase gene intI1 had its own promoter
region and attI1 recombination site; the 3¢-CS region pre-
sented qacED1 and sulI1 genes that confer resistance to qua-
ternary ammonium compounds and sulphonamide. A large
plasmid (size > 100 kb) was detected in the isolate by south-
ern blotting and produced a positive signal after hybrydiza-
tion with blaTEM-1 probe (data not shown). The amplicon
obtained by PCR was sequenced and appeared to corre-
spond to TEM-1 b-lactamase.
To our knowledge, this is the ﬁrst report showing a VIM-
type MBL in a P. mirabilis clinical isolate from Italy, and the
ﬁrst case to be detected in Europe outside of Greece [1–3].
It is of interest that the reported strain possessed two class
1 integrons (on chromosomal and plasmidic DNA) identical
to those recently described in a carbapenem-resistant Ente-
robacter cloacae strain isolated from a patient who died from
pneumonia [6], suggesting the spread of these elements by
gene cassette insertion into different bacterial species.
As already reported by Vourli et al. [3], the carbapenem
MICs were below the current resistant breakpoints. How-
ever, it was surprising to observe that our strain appeared
to be highly susceptible to several different b-lactams, and
the single criterion to suggest a search for MBL production
in this isolate was the prolonged therapeutic failure with
meropenem. These ﬁndings suggest a signiﬁcant variability in
VIM enzyme expression levels, and a poor correlation with
respect to in vitro susceptibility. A similar observation was
recently reported in VIM 1-positive Klebsiella pneumoniae
strains, which exhibited differences in imipenem-hydrolysing
activities that were not correlated with the respective carba-
penem MICs [8].
The acquisition of MBL determinants in P. mirabilis may be
of signiﬁcant concern for physicians because this organism is
usually resistant to colistin [9] and is poorly susceptible to
tigecycline [10], which represents an important option for
treating infections caused by multi-drug-resistant Gram-nega-
tive bacilli.
This report demonstrates the dissemination of the blaVIM-1
gene among different species of Enterobacteria. There is an
urgent need for accurate routine screening methods for
MBL-producing isolates, in order to identify them promptly.
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Abstract
Carbapenem-resistant or intermediate (MIC ‡1 mg/L) clinical
isolates (n = 12) of three species of Enterobacteriaceae (Klebsiella
pneumoniae, Klebsiella oxytoca and Escherichia coli) were character-
ized. The isolates harboured integrons containing the VIM-1
metallo-b-lactamase gene together with other resistance gene
cassettes. In particular, the CTX-M-2 gene was detected in four
of the K. pneumoniae isolates. The patient population was mostly
paediatric and characterized by severe underlying illnesses that
involved long-term hospitalization, major surgery and/or immu-
nosuppressive and broad-spectrum antibiotic therapy.
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Resistance to carbapenems may result from the presence of
metallo-b-lactamases (MBLs). These are zinc-dependent
b-lactam-hydrolysing enzymes with broad substrate speciﬁc-
ity that are not inhibited by clavulanic acid, sulbactam or
tazobactam. MBL genes can be chromosome- or plasmid-
borne, and are often located in integrons [1]. They are
usually found in nonfermenting Gram-negative bacteria and
are not frequent among the Enterobacteriaceae. However,
several recent studies have described both nonclinical [2] as
well as clinical isolates of MBL-producing enterobacteria
[2–6]. These included sporadic isolates, as well as isolates
from clonal epidemics and multiclonal endemic conditions
[6].
Carbapenem MICs are typically low and variable for MBL-
producing enterobacteria. This, together with the presence of
other b-lactamases, complicates their phenotypic detection in
routine tests. However, they can be readily detected with
speciﬁc phenotypic and molecular screening assays [7,8].
Between December 2005 and February 2008, several
carbapenem-resistant or intermediate enterobacterial isolates
were obtained from 12 hospitalized patients at Hospital Uni-
versitario La Paz, Madrid. Identiﬁcation and susceptibility
testing were conducted using the Wider (Francisco Soria
Melguizo SA, Madrid, Spain.) and Vitek 2 (bioMe´rieux, Barce-
lona, Spain.) automated systems. The isolates belonged
to three species (Klebsiella pneumoniae, Klebsiella oxytoca and
Escherichia coli). Single isolates from eight patients, and multi-
ple isolates from the other four patients, were obtained.
However, only one isolate per patient was analysed in detail.
One of the patients was an adult, hospitalized in the haema-
tology ward, whereas the others were children or infants
from the paediatric hospital. Patients were from different
wards and the isolates were well separated in time. Most
patients had severe illnesses involving major surgery and
long-term hospitalization (Table 1). Some of them had
repeated infections with different microorganisms, and all
had been receiving broad-spectrum antibiotic treatments. In
all cases, the infections were successfully treated, although
some patients had repeated septic episodes, which had to be
treated with a combination of antibiotics that included cipro-
ﬂoxacin. Clonal relatedness between K. pneumoniae isolates
was analysed using enterobacterial repetitive intergenic con-
sensus-PCR ﬁngerprinting with the primer ERIC2 [9] and
randomly ampliﬁed polymorphic DNA with the primers
OPI12 (5¢-AGAGGGCACA-3¢) and OPA18 (5¢-AGGTGAC
CGT-3¢) (Operon Technologies, Inc., Alameda, CA, USA).
Clonality was deﬁned using the criteria of Tenover et al.
[10]. The results obtained with these three primers were
consistent and indicated the presence of a major clone,
which included isolates 2, 3, 4, 8, 9, 10 and 11 (Tables 1
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